up
MRVI +20.1%, AMBA +8.5%, BGFV +7.3% (also increases dividend), QTRX +6.4%, LYFT +5.1% (raises 1Q21 adjusted EBITDA forecast), EYE +4.2%, DAR +2%, VEEV +1.7%, HPE +1.4%
Other news:
OVID +101.4% (Takeda Pharma (TAK) secures global rights from Ovid Therapeutics for Soticlestat; Ovid eligible to receive up to $856 mln in payments)
KMPH +71.6% (receives NDA approval from FDA for AZSTARYS)
TRXC +29.3% (Asensus Surgical (formerly TransEnterix) received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States)
TXMD +18.6% (EU & UK conclude decentralised procedure approval for Bijuva)
MFGP +17.8% (signs commercial agreement with Amazon Web Services)
GENE +15.4% (signs 3-year US co-exclusive licence agreement for COVID risk test)
GNLN +10.7% (acquired the Eyce brand and substantially all of the assets of Eyce, a manufacturer of specialty silicone smoking products)
EBON +10.5% (stock offering)
XCUR +7.5% (granted orphan drug designation by the FDA for Cavrotolimod)
DISH +7% (DISH Network and DraftKings (DKNG) announce strategic agreement with DraftKings app integration on DISH TV Hopper platform)
CAP +6.9% (enters into business combination agreement with Dorma)
DPW +6.1% (acquires 9.99% Equity Interest in SunLink Health Systems (SSY))
SRNE +5.6% (receives FDA clearance to proceed with Phase 1 study of STI-2099)
APPS +4.3% (acquires Triapodi (d/b/a Appreciate))
PAYA +4.3% (Point72 Asset Management discloses 5.5% stake)
BTAI +3.4% (provides update on its BXCL501 program for the acute treatment of dementia related agitation)
LVS +2.8% (reaches agreement to sell Las Vegas properties for $6.25 bln)
DKNG +2.6% (DISH Network and DraftKings announce strategic agreement with DraftKings app integration on DISH TV Hopper platform)
ATHM +2.5% (files for ADS offering)
HMC +2.1% (trucks set new February record)
MORF +1.7% (prices offering of 3.5 mln shares of common stock at $70.00 per share)
CHRS +1.7% (Coherus BioSciences and Junshi Biosciences announce initiation of rolling submission of BLA for toripalimab to the U.S. FDa for the treatment of nasopharyngeal carcinoma)
HSKA +1.2% (prices offering of 940,860 shares of its common stock at a $186.00 per share)
WPP +1.2% (acquires mobile technology provider NN4M)
KAR +1.1% (new CEO)
Analyst comments:
CASA +5.1% (upgraded to Neutral from Underweight at JP Morgan)
AA +4.3% (upgraded to Buy from Sell at Goldman)
DDD +3.9% (upgraded to Hold from Sell at Loop Capital), ST +3.9% (upgraded to Overweight from Neutral at JP Morgan)
RPD +3.8% (upgraded to Overweight from Neutral at Piper Sandler)
IRDM +3.2% (upgraded to Outperform from Mkt Perform at Raymond James)
ROKU +2.4% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
ETN +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
FSR +1% (upgraded to Peer Perform from Underperform at Wolfe Research)
